How Is the Pharmaceutical Industry Approaching Cannabis-Based Treatments for PMR?

PostedFebruary 24, 2026

UpdatedFebruary 24, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The growing interest in pharmaceutical cannabis for PMR has prompted the pharmaceutical industry to explore new treatment pathways. Companies are researching how cannabinoids can be standardised, safely formulated, and integrated with existing therapies to improve patient outcomes, while ensuring regulatory compliance and advancing industry innovation in bringing medical cannabis in market.

Industry Approaches to Cannabis-Based Treatments

Pharmaceutical companies are combining research, technology, and clinical expertise to refine cannabis-based options for PMR patients.

Standardised Formulations

Companies aim to produce consistent cannabinoid profiles that allow predictable dosing and reproducible results.

Clinical Trials

Ongoing studies examine safety, efficacy, and optimal delivery methods for cannabinoids in PMR treatment.

Regulatory Compliance

Strict guidelines ensure that cannabis-based medications meet high-quality standards before entering the market.

Integration with Existing Treatments

Pharmaceutical cannabis is being developed to complement traditional therapies, improving patient outcomes and adherence.

The rise of pharmaceutical cannabis for PMR represents a promising shift in how chronic pain conditions are managed. With ongoing drug development and a focus on industry innovation, patients may soon have access to well-tested, effective, and regulated cannabis-based therapies, marking a new era for PMR care.

If you’re exploring cannabis treatment options for polymyalgia rheumatica, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and polymyalgia rheumatica.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.